Coave Therapeutics
Coave Therapeutics is a clinical-stage biotechnology company that develops ligand-conjugated Adeno-Associated Virus (AAV) gene therapies for rare ocular and central nervous system diseases. Utilizing its proprietary ALIGATER platform, the company creates precision vectors designed for tissue-specific delivery and enhanced safety. Its lead program, CoTx-101, targets retinal vascular diseases such as neovascular age-related macular degeneration and diabetic macular edema.
Visit websiteParis, France
Biotechnology
Gene Therapy
Ophthalmology
Healthcare
Funding summary
- Total raised
- €53.2M
- Funding rounds
- 2
Investors in Coave Therapeutics
Investors on record for Coave Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Coave Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors